All In Biotech

Drug Trial Radar · NCT03758365

Evaluation of the Vasoconstriction Properties of MC2-01 Cream

A Randomized, Evaluator Blinded, Within Subject, Single-Centre Evaluation of the Vasoconstriction Properties of MC2-01 Cream, Compared to 5 Other Corticosteroids in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Nov 5, 2018

Primary completion

Nov 23, 2018

Study completion Nov 23, 2018

Sponsor

Lead sponsor
MC2 TherapeuticsIndustry
Sponsor type
Industry
First posted
Nov 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of this trial is to compare the vasoconstriction potential

Conditions

  • Vasoconstriction

Interventions

  • MC2-01 CreamDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • Clobetasol Propionate 0.05% LotionDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • Betamethasone Dipropionate 0.05% CreamDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • Triamcinolone Acetonide 0.1% CreamDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • Hydrocortisone Butyrate 0.1% CreamDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • Desonide 0.05% CreamDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

  • VehicleDrug

    Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and VehicleTime frame: Day 2
  2. Compare Local Tolerability of the MC2-01 Cream With Active Comparators and VehicleTime frame: Day 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CPCAD

    Nice, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.